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BY-NC-ND license (http://creativeAbstract Cancer death is usually caused by incurable drug-resistant and metastatic cancers.
Although tremendous progress has been made in anticancer drug development during the past
two decades, cancer medicine still faces unprecedented challenges associated with choosing
effective treatments for individual patients. Three recent reports have offered encouraging
approaches towards potentially personalized cancer drug selection.
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by-nc-nd/4.0/).Cancer is a heterogeneous disease, both among affected
individuals and within the same affected individual. Despite
the significant progress made in the past decade in devel-
oping new and/or more specifically-targeted cancer ther-
apeutics, the overall survival rates of many common
cancers have been slow to improve. This is largely due to
the suboptimal selection of therapeutic agents and/or
inevitable development of drug resistance. Thus, there is
an urgent need to develop precision and personalized
oncology. In three recent reports, investigators developed
different technical platforms that may allow the cancer
drug sensitivity and efficacy to be tested prior to full-scale
clinical treatments.13 If they become widely used, these
techniques may facilitate the development and imple-
mentation of personalized cancer medicine.
Cancer drug resistance remains a major cause of death
of cancer patients.4 For the past few decades, cancer drug
development has moved from empirical approaches that
broadly reduce cell proliferation or increase cell death toity of Chongqing Medical
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commons.org/licenses/by-nc-nd/more focused approaches that target well-defined genetic,
epigenetic and environmental drivers of cancer. This
progress is highlighted by the dramatic clinical responses
seen with drugs targeting the oncogenic BCR-ABL tyrosine
kinase fusion protein in chronic myelogenous leukemia
(CML) or oncogenic BRAF-V600E mutations in melanoma.
However, such molecular-targeted therapies are still asso-
ciated with drug resistance, just like the classical cytotoxic
chemotherapeutics. Thus, there is an urgent need to
develop clinically-relevant and novel in vivo models and
technologies to test and/or predict drug sensitivity and the
likelihood of resistance.4
For the past few decades, mouse models of cancer
development have provided immeasurable translational
value for cancer drug discovery.5 Mouse cancer models can
be used to confirm the biological relevance of candidate
targets on tumor growth, to establish therapeutic windows,
to determine efficacious drug targets, and to identify bio-
markers of the tumor response, although mouse models
often lack the predictive power for clinical success.5 In
recent years, increasing interest has been focused on the
development and characterization of patient-derivedand hosting by Elsevier B.V. This is an open access article under the
4.0/).
220 Commentarytumor xenograft (PDX) models for cancer research.6 PDX
models have been shown to retain the main histological and
genetic characteristics of the donor tumors, and remain
relatively stable across passages. Thus, PDX models may be
more predictive of clinical outcomes, and should have great
potential for preclinical drug evaluation, biomarker iden-
tification, and personalized cancer medicine. However, the
generation of PDX models can be time-consuming and
investigator-specific. Thus, simple, fast, and effective ap-
proaches should be devised to test cancer drugs. Three
recent studies may have made significant progress in this
regard.
Rubio-Perez et al reported a novel in silico analysis to
identify potentially effective cancer treatment strategies.3
This analysis took advantage of cancer genome data
generated by high-throughput next-generation sequencing
from pan-cancer cohorts that linked approved and experi-
mental therapeutics to specific genetic driver events. Using
these large pan-cancer patient cohorts, the investigators
developed a three-tier in silico prescription strategy by
assigning each patient the targeted therapeutic in-
terventions that would be most beneficial based on the
identified cancer driver events. By analyzing 6792 tumor
samples, the investigators identified 475 driver genes with
activating or loss-of-function alterations, such as somatic
mutations, copy-number amplifications, and/or gene fu-
sions. The second step involved collecting data on potential
anticancer drug treatments targeting driver genes,
including FDA-approved compounds and compounds in
clinical or preclinical development. Finally, these treat-
ments were prescribed in silico to individual patient sam-
ples based on the respective driver events.3 Interestingly,
the investigators found that using this strategy, only 5.9% of
patients would benefit from FDA-approved therapies.
However, the potential benefit of therapeutic intervention
could be increased to 40.2% if the tumor type, disease, and
off-target repurposing of FDA-approved drugs was consid-
ered. This model also predicted that an additional 33.1% of
patients may benefit from drugs currently in clinical trials
or in pre-clinical development. As expected, combination
therapies could provide beneficial effects for 39% of pa-
tients whose tumors contained multiple driver events.3 An
additional 80 potentially targetable driver genes were
identified in the in silico analysis.3 Thus, such in silico ap-
proaches may offer a powerful tool for oncologists to link
tumor-driving events with clinical treatments towards
personalized cancer medicine.
By taking completely different approaches, two inde-
pendent studies reported the use of newly engineered de-
vices to test drug sensitivity, and hence improve drug
selection, by directly injecting drugs into the patient and
analyzing the cancer response within the tumor microen-
vironment in vivo.1,2 Jonas et al engineered a small cylin-
drical device (820 mm in diameter) containing 16 discrete
reservoirs for releasing different drugs.1 The device was
implanted into tumors via a biopsy needle and left in situ
for 24 h, and then was removed with the tissue-containing
coring needle for an immunohistochemical analysis. Com-
binations of drugs or time-specific drug release can both be
achieved using this single device. The investigators showed
that there was a correlation between apoptosis and thedrug concentration.1 Of note, the investigators implanted
several devices into different areas of each tumor and used
replicate wells in each device, usually in the non-necrotic
periphery of the tumor, to overcome possible heterogene-
ity in the drug response. The investigators used doxorubicin
in animal models of human melanoma, prostate, and breast
cancers, and demonstrated that the device recapitulated
the systemic response. Finally, using a mouse model of
human triple-negative breast cancer, the investigators
showed that the ranking of effective therapies as deter-
mined with this device was the same as the whole animal
response to the systemically-administered drugs.
Klinghoffer et al developed a different technology plat-
form called CIVO, which contains an array of multiple nee-
dles and enables the simultaneous assessment of up to eight
drugs or drug combinations within a solid tumor in vivo.2
After drug injection, the needles were withdrawn, leaving
a 6-mm “track” containing the drug and tracking dye. After
incubation in situ for up to 72 h, the tumor tissues were
retrieved to assess the drugs’ effects on cancer cells. CIVO
offers an automated analytical program that assesses the
readouts and allows the cellular response to be correlated
with distinct microenvironments, offering the opportunity
for combinatorial interrogation of drugs.2 Using human lym-
phoma xenograft tumors treated with vincristine as a pre-
clinical model, Klinghoffer et al showed that the drug was
imaged within a 2-mm limit of distribution beyond the in-
jection epicenter, and the pharmacodynamic effects of
vincristine could be monitored using phosphohistone H3 and
CC3 assays. The investigators showed that a drug-resistant
version of the lymphoma model was unexpectedly respon-
sive to cyclophosphamide, as predicted with the CIVO de-
vice, and resistant tumorebearing animals treated with
cyclophosphamide were rendered tumor-free.2 These find-
ings highlight the importance of in-tumor screening of the
drug efficacy, because in vitro cell culture-based assays
failed to show these cells’ responsiveness to cyclophospha-
mide. The authors further showed that, after testing the
sensitivity of the lymphoma models to 97 approved cancer
drugs, the resistant cells were most sensitive to a previously
unidentified mTOR inhibitor.2 More importantly, the CIVO
platform has been moved forward into clinical testing, and
the insertion of thedevicewas shownwell-tolerated and safe
in the preliminary assessment in a small number of patients.
These in silico and/or device-based approaches for
cancer drug selection are novel and potentially trans-
formative. However, the in silico cancer drug prescription
analysis would reply on the availability of large cohorts of
genomic data for a given type of tumor. In addition, none of
the three approaches can easily overcome the issue of
tumor heterogeneity. The reported devices may thus have
physical limitations in detecting drug-resistant cells.
Moreover, the implantation of these devices may bypass
some important factors that limit drug diffusion, such as
the elevated interstitial fluid pressure and high concen-
trations of proteins in the extracellular fluid in tumor tis-
sues. A bigger challenge facing the field of cancer drug
development and selection is to identify reliable bio-
markers that reflect the drugs’ actions and effects in vivo.
Nonetheless, these investigations offer a promising start
towards personalized cancer medication.
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